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LETTER TO THE EDITOR
LY86, LRG1 and PDE9A genes overexpression 
in umbilical cord blood hematopoietic stem 
progenitor cells by acute myeloid leukemia (M3) 
microvesicles
Farnaz Razmkhah1,5* , Sorayya Ghasemi2, Masoud Soleimani3 and Sedigheh Amini Kafi‑abad4
Abstract 
Background: Microvesicles as a new device of cell–cell communication are potentially able to induce some pheno‑
types and genotypes of an origin cell in a target cell. We evaluate the role of leukemia microvesicles on the leukemia 
stem cells (LSCs)‑specific genes expression in healthy hematopoietic stem progenitor cells (HSPCs).
Methods: HL‑60 and NB‑4 cell lines were selected for microvesicles isolation by ultracentrifugation. Healthy HSPCs 
were obtained by magnetic association cell sorting (MACS) and CD‑34 micro‑beads from umbilical cord blood 
samples and then, were treated with 20 and 40 μg/ml leukemia microvesicles for 10 days, respectively. LY86, LRG1 and 
PDE9A genes expression as LSC specific genes were analyzed by QRT‑PCR. Surface CD‑34 antigen as stemness marker 
was measured by flow cytometry technique.
Results: Healthy HSPCs showed a significant increase in LSC specific genes expression after treatment with both 20 
and 40 μg/ml leukemia microvesicles at day 10. All studied groups showed more than 70% surface CD‑34 antigen at 
the last day of experiment which proved HSPCs stemness.
Conclusion: Our results suggest that healthy HSPCs can be transformed genetically by leukemia microvesicles 
to over express LSC specific genes. This may be further evidence of leukemia‑like transformation by leukemia 
microvesicles.
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To the respectful editor,
Microvesicles, as units of biological information, play a 
remarkable role in cell–cell interactions [1]. Numerous 
studies have shown that microvesicles are able to phe-
notypically transform a target cell (normal or tumor cell) 
to express some proteins [2], mRNAs [3] and microR-
NAs [4] of origin cell. For example, genomic instability as 
one of the first events in cancer, can be induced in nor-
mal transplant by leukemia microvesicles [5, 6]. It seems 
that microvesicles are passing a crucial step to be known 
as the first factors in cancer initiation, progression and 
invasion.
Acute myeloid leukemia (AML) is created from 
genomic alterations in a healthy hematopoietic stem cell 
(HSC) which is now called leukemia stem cell (LSC). This 
new cell keeps the ability of self-renewal but is affected 
by cell death, proliferation and differentiation [7]. In 
the leukemia microenvironment, leukemia and healthy 
cells, are in regular cell–cell communication through 
microvesicles. This study tries to determine whether leu-
kemia microvesicles are able to affect healthy HSPCs and 
dysregulate some genes such as LY86, LRG1 and PDE9A 
as LSC specific genes which have fully different patterns 
of expression in HSC and LSC [8].
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Isolated leukemia microvesicles from HL-60 and NB-4 
cell lines were assessed by DLS technique (Additional 
file  1) and showed that all microvesicles are less than 
1 μm in diameter which is the maximum limit of size for 
microvesicles (Additional file  2). Then healthy HSPCs 
from umbilical cord blood samples were treated with 20 
and 40 μg/ml leukemia microvesicles for 10 days. CD-34 
positive cells (98%) at day 0, still showed a high level of 
CD-34 antigen (more than 70%) as stemness marker after 
10-day treatment with leukemia microvesicles (Addi-
tional file 3).
Quantitative Real Time PCR (Table 1) was performed 
at day 10 of experiment to evaluate any fold change of 
three selected genes expression in healthy HSPCs. LY86 
gene expression significantly increased (P < 0.001) with 
both doses of leukemia microvesicles (20 and 40 μg/ml) 
in both studied groups (treatment with NB-4 and HL-60 
microvesicles) as shown in Fig. 1a. LY86 gene overexpres-
sion in HSPCs treated with NB-4 microvesicles was more 
remarkable than in HSPCs treated with HL-60 microvesi-
cles. This change is also dose dependent which is more 
distinct in HSPCs treated with 40  μg/ml than 20  μg/ml 
microvesicles.
The fold change of LRG1 gene expression in HSPCs 
was extremely high in both studied groups (P < 0.001). 
This increase was also dose dependent which was more 
in HSPCs treated with 40 μg/ml than 20 μg/ml leukemia 
microvesicles (Fig. 1b).
PDE9A gene expression, however, did not change 
remarkably in HSPCs treated with HL-60 microvesicles, 
increased significantly at the last day of experiment (day 
10) in a dose dependent manner (P < 0.05). This increase 
was more observable in HSPCs treated with NB-4 
microvesicles (Fig. 1c) without a dose dependent manner 
(P < 0.001).
It seems that microvesicles are powerful enough to 
affect the pattern of gene expression in a target cell since 
Cardiomyocytes derived microvesicles/exosomes dys-
regulated 333 genes in fibroblast including 175 up regu-
lations and 158 down regulations [9]. We previously 
showed the effect of leukemia microvesicles on survival 
and transformation of umbilical cord blood HSPCs [10–
12]. Another study revealed that LSCs microvesicles are 
able to induce proliferation and migration of myeloid leu-
kemia cells and support malignant cells [13]. In harmony 
with the above mentioned results, our study showed the 
ability of leukemia microvesicles in transformation of 
healthy HSPCs to over express LSC specific genes.
While leukemia microvesicles are able to transform a 
healthy HSPC through dysregulation of genes, mRNAs, 
microRNAs and proteins, there is always a question: 
will this transformation cause leukemia? This question 
is much more crucial when we know there is a close 
communication between leukemia and healthy cells in 
the bone marrow microenvironment through microves-
icles. Therefore, any leukemia-like transformation of 
healthy HSPCs may be a step toward the leukemia, 
which may result in leukemia progression and relapse.
Table 1 Primer sequences
Gene name Primer type Primer sequence
LY86 Forward 5‑GAA GGA AAG GAG AGC AGA TTT AC‑3
LY86 Reverse 5‑TGA TAG TAG CAT TGG CAC AGG‑3
LRG1 Forward 5‑TCT TGG AGC AGA CAG CGA C‑3
LRG1 Reverse 5‑TTT CGG CAG GTG GTT GAC AG‑3
PDE9A Forward 5‑ATA ACC ACA AGA AGT TGA CTC CTC‑3
PDE9A Reverse 5‑GCA GCT CAG CAT CTC ATT GG‑3
HPRT1 Forward 5‑CCT GGC GTC GTG ATT AGT G‑3
HPRT1 Reverse 5‑TCA GTC CTG TCC ATA ATT AGT CC‑3
Fig. 1 LY86, LRG1 and PDE9A genes expression in studied groups treated with HL‑60 microvesicles (H20: 20 μg/ml microvesicles, H40: 40 μg/
ml microvesicles) and NB‑4 microvesicles (N20: 20 μg/ml microvesicles, N40: 40 μg/ml microvesicles). a LY86 gene fold change, b LRG1 gene fold 
change and c PDE9A gene fold change in different groups of HSPCs. *P < 0.05, **P < 0.001
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Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s4016 4‑019‑0147‑8.
Additional file 1. Materials and methods. 
Additional file 2. DLS technique. Isolated microvesicles were quantita‑
tively size proved (80–1000 nm). 
Additional file 3. CD34 analysis at the end day of experiment. All studied 
groups expressed more than 70% stemness marker.
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